Why the study?
Current PET imaging with FDG lacks inflammatory cell specificity and is limited in coronary arteries by avid background myocardial uptake.
Novel PET tracers may overcome the limitations of FDG in imaging vascular inflammation, enabling better patient stratification for emerging immunomodulatory therapies.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open whether novel PET tracers can stratify patients for emerging immunomodulatory therapies.
PURPOSE OF REVIEW: To provide a focused update on recent advances in positron emission tomography (PET) imaging in vascular inflammatory diseases and consider future directions in the field. RECENT FINDINGS: F-fluorodeoxyglucose (FDG) can provide a useful marker of disease activity in several vascular inflammatory diseases, including atherosclerosis and large-vessel vasculitis, this tracer lacks inflammatory cell specificity and is not a practical solution for imaging the coronary vasculature because of avid background myocardial signal. To overcome these limitations, research is ongoing to identify novel PET tracers that can more accurately track individual components of vascular immune responses. Use of these novel PET tracers could lead to a better understanding of underlying disease mechanisms and help inform the identification and stratification of patients for newly emerging immune-modulatory therapies. Future research is needed to realise the true clinical translational value of PET imaging in vascular inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Ćorović et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: